On October 29, 2025, 10x Genomics announced the launch of its next-generation Chromium Flex assay, designed to help ...

While AI stocks slide, healthcare is soaring. XLV leads November gains, outperforming tech as investors rotate.

Detailed price information for Caribou Biosciences Inc (CRBU-Q) from The Globe and Mail including charting and trades.

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...

BERKELEY, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results ...

According to the 13F filing with the Securities and Exchange Commission dated Nov. 12, 2025, ARK Investment Management sold 395,617 shares of CRISPR Therapeutics AG during the third quarter. Its ...

ARK also continued its buying trend in CRISPR Therapeutics AG (NASDAQ:CRSP), acquiring 39,250 shares valued at $2,142,265. This purchase adds to the fund’s recent accumulation of CRISPR stock over the ...

Intellia’s shares plunged 23% after its Q3 results showed a pipeline setback. Nonetheless, Cathie Wood’s stake in the company ...

The Sickle Cell Disease Treatment Market offers significant opportunities with advancements in gene editing, stem cell therapies, and precision medicine driving innovation. Increased awareness and ...

Crispr stock jumped Monday while Intellia shares surged on promising updates for their gene-editing efforts in cholesterol ...

Investing.com -- Intellia Therapeutics Inc (NASDAQ:NTLA) stock soared 13.8% in premarket trading Monday after the gene editing company presented positive clinical data for its hereditary angioedema ...